PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Clinical trials for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT explained in plain language.
Never miss a new study
Get alerted when new PROSTATIC NEOPLASMS, CASTRATION-RESISTANT trials appear
Sign up with your email to follow new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat prostate cancer: Immune-Targeting drug combo enters final testing
Disease control Recruiting nowThis Phase 3 trial tests whether adding pasritamig, a drug that directs the body's T-cells to attack prostate cancer cells, to standard chemotherapy (docetaxel) can slow cancer growth better than chemotherapy alone. The study involves 800 men with metastatic castration-resistant …
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for Hard-to-Treat prostate cancer: experimental drug combo trial opens
Disease control Recruiting nowThis clinical trial is testing an experimental drug called opevesostat (MK-5684), either alone or combined with other cancer drugs, in people with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The study involves 220 participants and has t…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New 'See and Treat' approach targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests two copper-based drugs that work together: one helps doctors see prostate cancer tumors on scans, and the other delivers targeted radiation to kill them. The trial involves 54 men with a type of advanced prostate cancer that no longer responds to hormone therapy.…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug duo takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests two drugs—gedatolisib and darolutamide—together in men with metastatic castration-resistant prostate cancer (mCRPC), a type that has spread and no longer responds to standard hormone therapy. The first part finds the safest dose, and the second checks if the comb…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental combo aims to tackle Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called TVB-2640 combined with the standard drug enzalutamide (Xtandi) in 30 men whose prostate cancer has spread and stopped responding to hormone therapy. The main goal is to find the safest dose of TVB-2640 when used with enzalutamide and…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC